XM n’offre pas ses services aux résidents des États-Unis d’Amérique.

B
B

BectonDickinson

Actualités

Reuters - Il y a 2 semaines

U.S. STOCKS Guardforce AI, 2seventy Bio, GoDaddy

BUZZ-U.S. STOCKS ON THE MOVE-Guardforce AI, 2seventy Bio, GoDaddy Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were poised to open lower on Tuesday after starting the week on a strong footing, as investors awaited key inflation readings for clues on the Federal Reserve's interest-rate path.
A
Q
S
U
B
W
Reuters - Il y a 3 semaines

Navigate BioPharma Announces Collaboration with Becton, Dickinson to Advance Capabilities for Clinical Phases of Drug Development

BRIEF-Navigate BioPharma Announces Collaboration with Becton, Dickinson to Advance Capabilities for Clinical Phases of Drug Development Sept 7 (Reuters) - Becton Dickinson and Co BDX.N : NAVIGATE BIOPHARMA SERVICES, INC. ANNOUNCES COLLABORATION WITH BD (BECTON, DICKINSON AND COMPANY) TO ADVANCE CAPABILITIES FOR CLINICAL PHASES OF DRUG DEVELOPMENT S
B
Reuters - Il y a 1 mois

U.S. Acushnet Holdings, Insulet, Tracon Pharmaceuticals

U.S. RESEARCH ROUNDUP-Acushnet Holdings, Insulet, Tracon Pharmaceuticals Aug 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Acushnet Holdings, Insulet and Tracon Pharmaceuticals on Monday. HIGHLIGHTS * Acushnet Holdings Corp GOLF.N : Jefferies raises to buy from hold * Insulet Corp PODD.O : Citigroup raises to buy from neutral * Medical Properties Trust Inc MPW.N : JP Morgan cuts to underweight from neutral * Sar
C
N
N
R
A
B
E
F
H
Reuters - Il y a 2 mois

U.S. Celanese, Draftkings, Sovos Brands

U.S. RESEARCH ROUNDUP-Celanese, Draftkings, Sovos Brands Aug 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Celanese, Draftkings and Sovos Brands, on Wednesday. HIGHLIGHTS * Celanese Corp CE.N : JP Morgan cuts to neutral from overweight * Draftkings Inc DKNG.O : JP Morgan raises to neutral from underweight * Sovos Brands Inc SOVO.O : Piper Sandler cuts to neutral from overweight * Thoughtworks Holding Inc TWKS.O :
A
C
C
D
B
B
C
J
Reuters - Il y a 2 mois

Becton Dickinson and Co reports results for the quarter ended in June - Earnings Summary

Becton Dickinson and Co reports results for the quarter ended in June - Earnings Summary Becton Dickinson and Co BDX.N reported quarterly adjusted earnings of $2.96​​ per share for the quarter ended in June. The mean expectation of fifteen analysts for the quarter was for earnings of $2.91 per share. Revenue rose 5.1% to $4.88 billion from a year ago; analysts expected $4.84 billion.
B
Reuters - Il y a 2 mois

Becton Dickinson beats quarterly profit estimates on strong medical device sales

Becton Dickinson beats quarterly profit estimates on strong medical device sales Aug 3 (Reuters) - Becton Dickinson BDX.N beat Wall Street estimates for third-quarter profit on Thursday, helped by strong demand for its drug delivery devices and surgical equipment. One of the world's largest manufacturers and distributors of medical and surgical products such as needles, syringes and sharps disposal units is the latest company to benefit from an ongoing recovery in demand for non-urgent surgical
A
B
Reuters - Il y a 2 mois

Becton Dickinson Q3 Adjusted EPS USD 2.96 Vs. IBES Estimate USD 2.91

Aug 03 (Reuters) - Becton Dickinson Q3 revenue USD 4,878 million vs. IBES estimate USD 4,837 million. Q3 EPS USD 1.36 Outlook FY adjusted EPS USD 12.1-12.32
B
Reuters - Il y a 2 mois

What to Watch in the Day Ahead - Thursday, Aug 3

What to Watch in the Day Ahead - Thursday, Aug 3 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Apple Inc is expected to release third-quarter results, with investors focused on sales of iPhones.
A
A
A
G
H
R
B
S
W
C
T
Reuters - Il y a 2 mois

Medical device maker Steris lifts 2024 results view, records quarterly beat

Medical device maker Steris lifts 2024 results view, records quarterly beat Aug 1 (Reuters) - Medical equipment provider Steris STE.N on Tuesday raised its profit forecast for fiscal 2024 after strength in its core healthcare business boosted first-quarter results above Wall Street estimates. The Dublin-based company raised its forecasts to reflect the recent acquisition of Becton Dickinson and Co's BDX.N surgical instrumentation platform.
B
S
Reuters - Il y a 2 mois

Becton Dickinson and Co expected to post earnings of $2.91 a share - Earnings Preview

Becton Dickinson and Co expected to post earnings of $2.91 a share - Earnings Preview Becton Dickinson and Co BDX.N , BDX is expected to show a rise in quarterly revenue when it reports results on August 3. The Franklin Lakes New Jersey-based company is expected to report a 4.2% increase in revenue to $4.837 billion from $4.64 billion a year ago, according to the mean estimate from 12 analysts, based on Refinitiv data.
B
Reuters - Il y a 2 mois

Bd Names Joanne Waldstreicher To Board Of Directors

BRIEF-Bd Names Joanne Waldstreicher To Board Of Directors July 24 (Reuters) - Becton Dickinson and Co BDX.N : BD NAMES JOANNE WALDSTREICHER TO BOARD OF DIRECTORS Source text for Eikon: ID:nPn3vHxJJa Further company coverage: BDX.N
B
Reuters - Il y a 2 mois

U.S. STOCKS General Motors, Estee Lauder, IMAX

BUZZ-U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes climbed on Monday as investors braced for earnings from megacap growth and technology companies, while focusing on an interest rate decision from the Federal Reserve.
A
B
C
G
M
N
R
U
U
B
D
E
Reuters - Il y a 2 mois

Becton Dickinson shares hit record high after US FDA clears return of drug infusion system

Becton Dickinson shares hit record high after US FDA clears return of drug infusion system NEW YORK, July 24 (Reuters) - Shares of Becton Dickinson BDX.N hit an all-time high on Monday and were last up 6.1% after the medical device maker received U.S. Food and Drug Administration clearance late on Friday for the market return of its drug infusion system.
B
Reuters - Il y a 2 mois

U.S. STOCKS PaxMedica, Heron, Belite Bio

BUZZ-U.S. STOCKS ON THE MOVE-PaxMedica, Heron, Belite Bio Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes climbed on Monday as investors braced for earnings from megacap growth and technology companies, while focusing on an interest rate decision from the Federal Reserve.
A
B
C
G
H
M
N
O
U
U
B
E
Reuters - Il y a 2 mois

Becton Dickinson soars to record high on FDA nod for Alaris infusion system

BUZZ-Becton Dickinson soars to record high on FDA nod for Alaris infusion system Updates stock activity ** Shares of Becton Dickinson BDX.N up 6.9% at $283.12, hits record high $287.32 early Mon, after medical device maker gets regulatory nod for its drug infusion system ** Late Fri, co said updated Alaris Infusion System received 510(k) clearance from U.S.
B
Reuters - Il y a 2 mois

U.S. STOCKS Apple, Quince, Syndax Pharma

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Quince, Syndax Pharma Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set to open higher on Monday as investors geared up for earnings from megacap growth and technology companies, with focus also on a rate decision from the Federal Reserve later this week.
A
B
C
G
M
N
R
U
B
E
Reuters - Il y a 2 mois

Becton Dickinson jumps on FDA nod for Alaris infusion system, analyst upgrades

BUZZ-Becton Dickinson jumps on FDA nod for Alaris infusion system, analyst upgrades ** Shares of medical device maker Becton Dickinson BDX.N jump 6.4% to $281.79 premarket after co gets regulatory nod for its drug infusion system ** BDX set to open at record high, if gains hold ** Late Fri, co said updated Alaris Infusion System received 510(k) clearance from U.S.
B
Reuters - Il y a 2 mois

U.S. Apple, Deckers Brands, Microsoft

U.S. RESEARCH ROUNDUP- Apple, Deckers Brands, Microsoft July 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apple, Deckers Brands and Microsoft on Monday. HIGHLIGHTS * Apple Inc AAPL.O : Wells Fargo raises target price to $225 from $210 * Deckers Brands DECK.N : Piper Sandler raises target price to $595 from $535 * Lockheed Martin Corp LMT.N : Jefferies cuts target price to $505 from $525 * Microsoft MSFT.O : Gol
A
A
A
A
B
C
M
V
A
A
B
Reuters - Il y a 2 mois

BD Receives FDA 510(K) Clearance For Updated BD Alaris Infusion System

BRIEF-BD Receives FDA 510(K) Clearance For Updated BD Alaris Infusion System July 21 (Reuters) - Becton Dickinson and Co BDX.N : BD RECEIVES FDA 510(K) CLEARANCE FOR UPDATED BD ALARIS™ INFUSION SYSTEM BD - DOES NOT EXPECT ANY MATERIAL INCREMENTAL REVENUE CONTRIBUTION FROM BD ALARIS INFUSION SYSTEM FOR REMAINDER OF FY23; BD - EXPECTS TO ABSORB INI
B
Reuters - Il y a 3 mois

BD To Sell Surgical Instrumentation Platform To Steris

BRIEF-BD To Sell Surgical Instrumentation Platform To Steris June 20 (Reuters) - Becton Dickinson and Co BDX.N : BD TO SELL SURGICAL INSTRUMENTATION PLATFORM TO STERIS BD - OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED BD: TO SELL ITS SURGICAL INSTRUMENTATION PLATFORM TO STERIS FOR $540 MILLION BD - IF DEAL CLOSES AS EXPECTED WITHIN BD'S FISCAL YEAR 2023, IMPACT TO ADJUSTED EARNINGS PER SHARE (EPS) WOULD BE IMMATERIAL BD - DIVESTITURE WILL INCLUDE V.
B
S

Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Nous utilisons des cookies pour vous donner la meilleure expérience possible de notre site internet. En savoir plus ou modifier vos paramètres de cookies.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques